During the annual salmon run last fall, University of Washington researchers pulled salmon DNA out of thin air and used it to ...

TriLink BioTechnologies senior scientist Dr Cody Palumbo discusses the blockers to manufacturing mRNA-based gene editing ...

Data highlight encouraging clinical activity of EO1001 and differentiated preclinical efficacy of EO?4426 in highly resistant, replication?stress-driven tumors MENLO PARK, CA / ACCESS Newswire / ...

Statement 1: DNA synthesis always proceeds in the 5' to 3' direction.

Artios Pharma, a Babraham-based biopharma company realising the therapeutic power of targeting the DNA damage response in ...

Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ...

In their common MOU, Mainz Biomed and OncoVanguard8 have outlined core commercial, legal and regulatory terms as well as the ...

The firm will use the funds to support clinical trials of its ATR inhibitor alnodesertib and its pol theta inhibitor ART6043.

DNA replication, the fundamental process of copying a DNA molecule, is described as semiconservative due to its unique ...

Artios Pharma is working on a pipeline of oncology assets, led by alnodesertib, currently being tested for second-line ...

Funding advances Phase 2 expansion cohorts in pancreatic and colorectal cancer in ATM-negative patients for Artios’ potential ...

Artios Pharma, which looking for newer targets that, like PARP inhibitors, affect the way tumors fix themselves, said its ...